Subscribe to the Voices in Health Care Value newsletter to be notified about new research, policies, and upcoming events relevant to the health care value community.
Welcome to the ninth issue of Voices in Health Care Value, the newsletter of the Research Consortium for Health Care Value Assessment (RC-HCVA). This issue features work from our colleagues at the Pharmaceutical Value (pValue) – headquartered within the University of Colorado’s Anschutz Medical Campus. We appreciate your comments and inputs to subsequent issues. If you are interested in becoming a Colleague in Value (individuals and groups who work in this area or who are simply interested in its findings) please register here.
By George Miller
With funding from the Pharmaceutical Research and Manufacturers of America (PhRMA), the Research Consortium for Health Care Value Assessment (RC-HCVA) has established a grant center to support research projects that address issues in health care value.1 The first initiative of the center has been to fund seven short and timely projects on issues related to enhancing health care value in the context of the COVID-19 pandemic. Each project has resulted in a short report to be published in a Health Affairs Blog series this fall. The researchers will also present their work in a webinar that is free and open to the public on October 8, 2020 from 1:00 to 3:00 PM EDT. Registration for the event can be found here.2
The series addresses a broad spectrum of topics in health care value in the context of the COVID-19 pandemic and its aftermath. In Taming the Paper Tiger, David Cutler (Harvard University) describes reasons for high administrative costs in health care, discusses the need to reduce them, and presents ideas for addressing the issue, which persists during the pandemic and will continue after it has been controlled.
The pandemic has resulted in unprecedented adoption of telehealth services as a safe way to deliver health care for some services without the risks inherent in in-person contacts. Christina Cutter, Nicholas Berlin, and Mark Fendrick (University of Michigan) propose policy and research agendas to inform a value-based approach to continuing the use of telehealth in a post-pandemic environment in their report titled Establishing a Value-Based “New Normal” for Telehealth.
As manufacturers work on treatments, cures, vaccines, and diagnostics to address COVID-19, researchers have begun to consider how these new technologies should be priced. In Applying Value Assessment to the Health Care Sector for COVID-19, William Padula (University of Southern California) describes problems with using traditional cost-effectiveness analysis to inform such price setting and proposes an alternative method based on budget impact analysis.
COVID-19 has resulted in major swings in the provision of elective clinical services. Bruce Stuart (University of Maryland, Baltimore) describes this phenomenon, considers how the supply of such services is likely to be affected once the crisis is over, and discusses a number of relevant policy issues in How the COVID-19 Pandemic Has Affected Provision of Elective Services by American Health Care Providers: The Challenges Ahead.
Two of the research projects have addressed the natural experiment that has resulted from the reduction in both high- and low-value care that has occurred in the context of the pandemic. In Opportunities to Improve Value in Health Following the COVID-19 Pandemic, Kevin Griffith and Melinda Buntin (Vanderbilt University) describe several experimental designs to improve our understanding of this reduction in wasteful services and consider ways to address it post pandemic. In The COVID-19 Pandemic Can Help Us Understand Low-Value Health Care, Jodi Segal (Johns Hopkins University) and Allison Oakes (University of Pennsylvania) describes how this natural experiment can expand our understanding of low-value care and inform the development of a research agenda and policies to permanently reduce it.
Finally, the COVID-19 pandemic has highlighted the health disparities that persist throughout the U.S. health care system. Harold Pollack and Caroline Kelly (University of Chicago) explore some of the challenges that must be overcome to reduce these disparities and discusses steps to reduce them in preparation for the next public health crisis in their paper, COVID-19 and Health Disparities – Insights from Key Informant Interviews.
More information on the grant center and this initial series of studies will be forthcoming in future issues of Voices in Health Care Value and on the RC-HCVA website. In the meantime, we encourage interested readers to watch for these blogs in Health Affairs and to register for the October 8 webinar.
Pharmaceutical Value (pValue) – headquartered within the University of Colorado’s Anschutz Medical Campus – aims to apply and test novel methods for value assessment that encourages stakeholder engagement and promotes value-based decision making. pValue is a recipient of the PhRMA Foundation’s Value Assessment Initiative Centers of Excellence Award.
Traditional measures of value used in cost-effectiveness analyses are not, by definition, fully comprehensive or sufficiently flexible to allow for the inclusion of all the criteria that patients, payers, clinicians, or other health care stakeholders care about. Multi-criteria decision analysis (MCDA) offers a scientifically rigorous decision-making tool capable of including multiple criteria that are important to stakeholders. MCDA has been applied in a variety of sectors, such as investment banking and environmental management, but applications in US healthcare decision making have been limited.
MCDA can improve decision making in health care by engaging key stakeholders and by capturing and weighing criteria not found in traditional measures of value, for example novelty, severity of disease, quality of evidence, and family burden. By encouraging a comprehensive understanding of value, MCDA offers an opportunity to systematically weigh non-traditional aspects of value that fall outside traditional measures of value.
The University of Colorado’s pValue initiative will explore how MCDA can add information on value to improve decision making in health care.
R. Brett McQueen, PhD
Kavita V. Nair, PhD
Jonathan D. Campbell, PhD
Former Director and Steering Committee Member
Melanie D. Whittington, PhD
Former Investigator and pValue collaborator
Sign up for Voices in Health Care Value
1. We thank PhRMA for funding the research grant center and for extending complete independence to Altarum to select researchers and specific topics. Altarum and Health Affairs retained all editing rights.
2. An agenda for the webinar that includes full author affiliation information can also be found at this link.
The Research Consortium for Health Care Value Assessment is a partnership between Altarum and VBID Health, with funding from the PhRMA Foundation as part of its Value Assessment Initiative, established to promote the pursuit of value in health care delivery in the U.S. Follow us at @ValueConsortium.
Beth Beaudin-Seiler, Ph.D.
3520 Green Court, Suite 300
Ann Arbor, MI 48105